Shop by goal
Popular compounds
Research resources
Recently viewed
Orforglipron: A Research Guide to the First Oral Non-Peptide GLP-1 Receptor Agonist
Short answer: orforglipron (LY3502970) is Eli Lilly’s once-daily oral GLP-1 agonist — and the key word is small molecule , not a peptide . That is why it can be a tablet taken with no food or water restriction, and why it is far cheaper to make at scale. Phase 3 ATTAIN-1 reported ~ 12.4% mean weight loss at 72 weeks at the top dose; ATTAIN-2 (diabetes) ~10.5% with HbA1c down ~1.8%. Lilly has triggered global regulatory submissions, but it has no marketing authorisation anywhere as of mid-2026. Because it is not a peptide, it sits outside New-U’s research catalogue. Part of our next obesity-research wave overview.
Plain-English summary. Orforglipron is an unapproved, investigational drug. The FDA, MHRA and EMA have not authorised it. It is a small molecule , a different chemical class from the research peptides New-U catalogues. This page is general information, not legal or medical advice; do not use unapproved compounds on people.
What orforglipron actually is — and why “non-peptide” is the headline
Semaglutide, tirzepatide and retatrutide are all peptides — chains of amino acids. Peptides are normally destroyed in the gut, which is why they are injected (or, for oral semaglutide, packaged with absorption enhancers and dosed under strict empty-stomach rules). Orforglipron is different: it is a small molecule that happens to fit and activate the GLP-1 receptor. Small molecules:
Its developmental code is LY3502970 . The chemistry and trial detail are indexed under PubMed: orforglipron / LY3502970.
Mechanism: same receptor, different key
Orforglipron acts on the same GLP-1 receptor as the injectable peptides — suppressing appetite, slowing gastric emptying and improving glucose-dependent insulin secretion. The difference is purely the molecule doing the activating: a designed small-molecule agonist rather than a peptide analogue of GLP-1 itself. Same biology downstream; radically different manufacturing and delivery upstream.
The ATTAIN Phase 3 evidence
In ATTAIN-1 all three doses (6 mg, 12 mg, 36 mg once daily) met the primary endpoint, with dose-dependent secondary endpoints (proportions reaching ≥10%, ≥15% and ≥20% loss, plus waist-circumference reductions). The safety profile was consistent with the GLP-1 class — mostly mild-to-moderate gastrointestinal events. Following the Phase 3 readouts, Eli Lilly triggered global regulatory submissions.
Why a 12% pill can beat a 20% injection. On raw magnitude, the injectable dual and triple agonists out-lose orforglipron. But a daily tablet with no cold chain, lower cost and no needle could reach far more people — so its public-health footprint may exceed its per-patient percentage. Access, not just efficacy, is the orforglipron story.
How orforglipron compares
Orforglipron and research compounds
This is the one compound in the next-wave set that is not a peptide , so it falls outside a research-peptide catalogue entirely. New-U does not sell orforglipron , and any “research orforglipron” listing should be treated with caution as it is a proprietary small molecule, not a reference peptide. The verifiable GLP-1-class research peptides New-U does catalogue are:
Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption . For the broader oral-vs-injectable debate, see oral vs injectable GLP-1 research.
Frequently Asked Questions
What is orforglipron? Eli Lilly’s investigational once-daily oral GLP-1 agonist (LY3502970) — a small molecule, not a peptide.
Is it a peptide? No — it is a small molecule, which is why it works as a daily tablet and is cheap to manufacture at scale.
Is orforglipron approved? No. As of mid-2026 there is no marketing authorisation, though Lilly has filed global regulatory submissions.
How much weight loss? ~12.4% mean at 72 weeks (ATTAIN-1, top dose); ~10.5% in the diabetes trial.
Does New-U sell it? No — it is a small molecule outside a research-peptide catalogue. New-U carries the GLP-1-class reference peptides (semaglutide, tirzepatide, retatrutide). Research use only.
Related Reading
Primary sources & further reading
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified GLP-1-Class Research Peptides
Orforglipron is a small molecule, but the GLP-1-class research peptides — semaglutide, tirzepatide and retatrutide — are catalogued by New-U as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy research peptides from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io